Improving adherence to urate-lowering therapy in people living with gout

Matthew J Coleshill^{1

2}, Eindra Aung^{1

2}, Amy D Nguyen^{1

3}, Sophie L Stocker^{1

2}, Melissa T Baysari⁴, Bishoy Kamel^{1

2}, Marcel Schulz^{1

2}, Andrew J McLachlan⁵, Richard O Day^{1

2}

Affiliations

¹ St Vincent's Clinical School, UNSW Medicine, Sydney, New South Wales, Australia.
² Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, New South Wales, Australia.
³ Centre for Health Systems & Safety Research, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.
⁴ Faculty of Health Sciences, University of Sydney, Sydney, New South Wales, Australia.
⁵ Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.

Editorial

Matthew J Coleshill et al. Int J Rheum Dis. 2019 Apr.

. 2019 Apr;22(4):542-544.

doi: 10.1111/1756-185X.13566.

¹ St Vincent's Clinical School, UNSW Medicine, Sydney, New South Wales, Australia.
² Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, New South Wales, Australia.
³ Centre for Health Systems & Safety Research, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.
⁴ Faculty of Health Sciences, University of Sydney, Sydney, New South Wales, Australia.
⁵ Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.

No abstract available

Comment on

Achieving treat to target in gout: a clinical practice improvement project.
Lim AY, Shen L, Tan CH, Lateef A, Lau TC, Teng GG. Lim AY, et al. Scand J Rheumatol. 2012;41(6):450-7. doi: 10.3109/03009742.2012.689325. Epub 2012 Jul 28. Scand J Rheumatol. 2012. PMID: 22839705